Blog

Hello everyone! I am Kristen Getz, the Product Owner (PO) of Q-interactive®. As the PO, my main role is to champion the customer’s needs throughout the product development journey. Before joining Pearson, I spent 14 years in clinical practice. At Pearson I have been focused on developing tests and improving our platforms for clinicians. My passion for assessments comes from my experience working with children and adults, aiming to create products that are psychometrically sound and user-friendly while saving valuable time.

The Q-interactive platform embodies everything I believe in and strive for: precision, intuitiveness, and innovation. Q-interactive is revolutionizing the field of psychological assessment, offering more accurate and creative ways to measure constructs. The new app's underlying technology has unlocked a plethora of new features that we will be gradually releasing, all based on feedback from you, our valued customers. Stay tuned because we know you will be excited about what is coming next!

June 25, 2024 - Pearson, the world's leading learning company, is excited to announce its 2024 ADHD Virtual Summit will take place on Tuesday, October 8, and Wednesday, October 9. Designed for clinical professionals and the wider ADHD community, the event features an international line-up of experts, the most pressing ADHD topics today, and the opportunity for clinicians to earn Continuing Education (CE) credits. Registration is open now.

MPQ coauthors John Kamp, PhD, and Martin Sellbom, PhD, answer some frequently asked questions about the newly published Multidimensional Personality Questionnaire (MPQ).

Pearson staff consider diversity, equity, and inclusion (DE&I) throughout test planning/research planning, development, and revision process. There are both general and specific considerations for DE&I for any project that is being revised or developed. The general considerations for DE&I in clinical assessment development at Pearson will be summarized below, as well as specific considerations for the planning, initiation, content/item development, data collection, scoring and data analysis, and test manual writing phases. 

This information is a summary of the complex process undergone by the Pearson staff to ensure that DE&I considerations are embedded within every phase of product planning and development. While this is by no means an exhaustive representation of our efforts, our staff is dedicated to continuing our learning and application of DE&I principles. 

Q&A with BOT-3 Product Manager, Melinda Cooper

The BOT™-3 is nearly ready to launch! You’ve asked such thoughtful questions about the new test, so we’ve assembled the most common ones, then grouped them by topic to make it easier for you to find the answers you’re seeking.

Links to get more information about the BOT-3 , BOT-3 Brief, and budget-stretching bundling options can be found at the end of this Q&A. Please reach out to your assessment consultant if you have questions we have not covered here.

As people turn to social media and AI for answers about mental health and learning disabilities, experts encourage formal clinical assessment over social self-diagnosis.

We are proud to announce the new Call for Research published by Pearson Clinical Assessment. Our goal is to ensure that Pearson assessments comply with the highest standards of quality and support research that investigates the validity or efficacy of our products. We are inviting United States-based faculty members, graduate students, and qualified researchers to submit their proposals no later than August 16, 2024.

Over the last ten years, the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-3), a leading developmental assessment for children ages 1–42 months, has been referenced as an endpoint in 145 clinical trials (Citeline, 2024). Of those, 6.21% have included sites in the Finno-Ugric countries of Estonia, Finland, and Hungary.